Rodrigo Quera

Rodrigo Quera

Auto-generated profile, based on publicly available information

Rodrigo Quera

Universidad de los Andes, Clínica Universidad de Los Andes, (1)Programa Enfermedad Inflamatoria Intestinal, Santiago, Chile

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in Gastroenterology
Verified
Journal Article
Closed access
EQEamonn Quigley
Eamonn Quigley
RQRodrigo Quera
Rodrigo Quera

10 December 2009 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
CBCaroll J. Beltrán
Caroll J. Beltrán
LNLucía E. Núñez
Lucía E. Núñez
DDDavid Díaz-Jiménez
David Díaz-Jiménez
NFNancy Farfan
Nancy Farfan
ECEnzo Candia
Enzo Candia
MHMarcela A. Hermoso
Marcela A. Hermoso

28 September 2017 in World Journal of Gastroenterology
Verified
Journal Article
Open access
KDKaren Dubois-Camacho
Karen Dubois-Camacho
POPayton A Ottum
Payton A Ottum
DFDaniel Franco-Muñoz
Daniel Franco-Muñoz
MFMarjorie De la Fuente
Marjorie De la Fuente
ATAlejandro Torres-Riquelme
Alejandro Torres-Riquelme
MHMarcela Hermoso
Marcela Hermoso
Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology

1 March 2014 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
RQRodrigo Quera
Rodrigo Quera
RERicardo Espinoza
Ricardo Espinoza
CECamila Estay
Camila Estay
DRDaniela Rivera
Daniela Rivera

13 March 2023 in Drugs
Verified
Journal Article
Open access
PDF file
PNPaulina Núñez
Paulina Núñez
RQRodrigo Quera
Rodrigo Quera
AYAndres J Yarur
Andres J Yarur
In recent years, better knowledge of the pathophysiology of inflammatory bowel diseases (IBD) has led to a relevant expansion of the therapeutic arsenal for these conditions. Janus kinase (JAK) inhibitors are a family of small molecules that block one or more of the intracellular tyrosine kinases, including JAK-1, JAK-2, JAK-3 and TYK-2. Tofacitinib, a non-selective small molecule JAK inhibitor, and upadacitinib and filgotinib, which are selective JAK-1 inhibitors, have been approved by the US Food and Drug Administration (FDA) for moderate-to-severe active ulcerative colitis. Compared to biological drugs, JAK inhibitors have a short half-life, rapid onset of action, and no immunogenicity. Both clinical trials and real-world evidence support the use of JAK inhibitors in the treatment of IBD. However, these therapies have been linked with multiple adverse events (AEs) including infection, hypercholesterolemia, venous thromboembolism, major adverse cardiovascular events, and malignancy. While early studies recognized several potential AEs, post-marketing trials have shown that tofacitinib may increase the risk of thromboembolic diseases and major cardiovascular events. The latter are seen in patients aged 50 years or older with cardiovascular risk factors. Hence, the benefits of treatment and risk stratification need to be considered when positioning tofacitinib. Novel JAK inhibitors with a more selective effect on JAK-1 have proven to be effective in both Crohn’s disease and ulcerative colitis, offering a potentially safer and efficacious therapeutic option to patients, including those with previous non-response to other therapies such as biologics. Nevertheless, long-term effectiveness and safety data are required.

12 November 2018 in Tumor Biology
Verified
Journal Article
Open access
PDF file
MFMarjorie De la Fuente
Marjorie De la Fuente
GLGlauben Landskron
Glauben Landskron
DPDaniela Parada
Daniela Parada
KDKaren Dubois-Camacho
Karen Dubois-Camacho
DSDaniela Simian
Daniela Simian
MHMarcela A Hermoso-R
Marcela A Hermoso-R
A complex network of chemokines can influence cancer progression with the recruitment and activation of hematopoietic cells, including macrophages to the supporting tumor stroma promoting carcinogenesis and metastasis. The aim of this study was to investigate the relation between tissue and plasma chemokine levels involved in macrophage recruitment with tumor-associated macrophage profile markers and clinicopathological features such as tumor–node–metastases stage, desmoplasia, tumor necrosis factor-α, and vascular endothelial growth factor plasma content. Plasma and tumor/healthy mucosa were obtained from Chilean patients undergoing colon cancer surgery. Chemokines were evaluated from tissue lysates (CCL2, CCL3, CCL4, CCL5, and CX3CL1) by Luminex. Statistical analysis was performed using Wilcoxon match-paired test ( p < 0.05). Macrophage markers (CD68, CD163, and iNOS) were evaluated by immunohistochemistry samples derived from colorectal cancer patients. Correlation analysis between chemokines and macrophage markers and clinicopathological features were performed using Spearman’s test. Plasmatic levels of chemokines and inflammatory mediators’ vascular endothelial growth factor and tumor necrosis factor-α were evaluated by Luminex. Tumor levels of CCL2 (mean ± standard deviation = 530.1 ± 613.9 pg/mg), CCL3 (102.7 ± 106.0 pg/mg), and CCL4 (64.98 ± 48.09 pg/mg) were higher than those found in healthy tissue (182.1 ± 116.5, 26.79 ± 22.40, and 27.06 ± 23.69 pg/mg, respectively p < 0.05). The tumor characterization allowed us to identify a positive correlation between CCL4 and the pro-tumor macrophages marker CD163 ( p = 0.0443), and a negative correlation of iNOS with desmoplastic reaction ( p = 0.0467). Moreover, we identified that tumors with immature desmoplasia have a higher CD163 density compared to those with a mature/intermediated stromal tissue ( p = 0.0288). Plasmatic CCL4 has shown a positive correlation with inflammatory mediators (tumor necrosis factor-α and vascular endothelial growth factor) that have previously been associated with poor prognosis in patients. In conclusion High expression of CCL4 in colon cancer could induce the infiltration of tumor-associated macrophages and specifically a pro-tumor macrophage profile (CD163+ cells). Moreover, plasmatic chemokines could be considered inflammatory mediators associated to CRC progression as well as tumor necrosis factor-α and vascular endothelial growth factor. These data reinforce the idea of chemokines as potential therapeutic targets or biomarker in CRC.